Skip to content
2000
image of Smart Inhalers and Nanotechnology-driven Inhalation Drug Delivery System: A Review

Abstract

The development of smart inhalers and nanotechnology-driven inhalation drug delivery systems has transformed the management of many respiratory diseases. Smart inhalers equipped with sensors and digital connectivity enable real-time monitoring, adherence tracking, and personalized dosing, addressing the key limitations of conventional inhalers. Nanotechnology-based approaches, such as liposomes, solid lipid nanoparticles, and polymeric nanoparticles, enhance drug solubility, targeted delivery, and sustained release profiles. The integration of these technologies has led to improved disease management and patient quality of life. Advantages of this system include deeper lung penetration, increased bioavailability, and reduced side effects. This review summarizes recent advancements in these technologies, their clinical applications, current challenges, regulatory approvals, and future directions for optimizing inhalation drug delivery systems.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X448056251210224544
2026-04-06
2026-04-17

  • From This Site

    /content/journals/crmr/10.2174/011573398X448056251210224544
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Momtazmanesh S. Moghaddam S.S. Ghamari S-H. Global burden of chronic respiratory diseases and risk factors, 1990-2019: An update from the Global Burden of Disease Study 2019. EClinicalMedicine 2023 59 101936 10.1016/j.eclinm.2023.101936 37229504
    [Google Scholar]
  2. Kumar Subramani P. P N R, Narayanasamy D. NP R, Narayanasamy D. The role of pulmonary drug delivery in modern therapeutics: An overview. Cureus 2024 16 9 68639 10.7759/cureus.68639 39371739
    [Google Scholar]
  3. Longest P.W. Bass K. Dutta R. Use of computational fluid dynamics deposition modeling in respiratory drug delivery. Expert Opin. Drug Deliv. 2019 16 1 7 26 10.1080/17425247.2019.1551875 30463458
    [Google Scholar]
  4. Paranjpe M. Müller-Goymann C. Nanoparticle-mediated pulmonary drug delivery: A review. Int. J. Mol. Sci. 2014 15 4 5852 5873 10.3390/ijms15045852 24717409
    [Google Scholar]
  5. Sosnowski T.R. Towards more precise targeting of inhaled aerosols to different areas of the respiratory system. Pharmaceutics 2024 16 1 97 10.3390/pharmaceutics16010097 38258107
    [Google Scholar]
  6. Hakizimana A. Devani P. Gaillard E.A. Current technological advancement in asthma care. Expert Rev. Respir. Med. 2024 18 7 499 512 10.1080/17476348.2024.2380067 38992946
    [Google Scholar]
  7. Ravichandran R. Nanotechnology-based drug delivery systems. NanoBiotechnol 2009 5 1-4 17 33 10.1007/s12030‑009‑9028‑2
    [Google Scholar]
  8. Ndebele R.T. Yao Q. Shi Y.N. Progress in the application of nano- and micro-based drug delivery systems in pulmonary drug delivery. BIO Integration 2022 3 2 71 83 10.15212/bioi‑2021‑0028
    [Google Scholar]
  9. Shakshuki A. Agu R.U. Improving the efficiency of respiratory drug delivery: A review of current treatment trends and future strategies for asthma and chronic obstructive pulmonary disease. Pulm. Ther. 2017 3 2 267 281 10.1007/s41030‑017‑0046‑2 32026344
    [Google Scholar]
  10. Bosnic-Anticevich S. Bakerly N.D. Chrystyn H. Hew M. van der Palen J. Advancing digital solutions to overcome longstanding barriers in asthma and COPD management. Patient Prefer. Adherence 2023 17 259 272 10.2147/PPA.S385857 36741814
    [Google Scholar]
  11. Jansen E.M. van de Hei S.J. Dierick B.J.H. Kerstjens H.A.M. Kocks J.W.H. van Boven J.F.M. Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: A narrative review of the clinical and economic case for smart inhalers. J. Thorac. Dis. 2021 13 6 3846 3864 10.21037/jtd‑20‑2360 34277075
    [Google Scholar]
  12. Matamoros O. Nava J.G. Escobar J.J. Ceballos Chávez B.A. Artificial intelligence for quality defects in the automotive industry: A systemic review. Sensors 2025 25 5 1288 10.3390/s25051288 40096013
    [Google Scholar]
  13. Chan A.H.Y. Pleasants R.A. Dhand R. Digital inhalers for asthma or chronic obstructive pulmonary disease: A scientific perspective. Pulm. Ther. 2021 7 2 345 376 10.1007/s41030‑021‑00167‑4 34379316
    [Google Scholar]
  14. Roche N. Dekhuijzen P.N.R. The evolution of pressurized metered-dose inhalers from early to modern devices. J. Aerosol Med. Pulm. Drug Deliv. 2016 29 4 311 327 10.1089/jamp.2015.1232 26824873
    [Google Scholar]
  15. Gupta R.S. Fierstein J.L. Boon K.L. Sensor-based electronic monitoring for asthma: A randomized controlled trial. Pediatrics 2021 147 1 20201330 10.1542/peds.2020‑1330 33386336
    [Google Scholar]
  16. Pilcher J. Holliday M. Ebmeier S. Validation of a metered dose inhaler electronic monitoring device: Implications for asthma clinical trial use. BMJ Open Respir. Res. 2016 3 1 000128 10.1136/bmjresp‑2016‑000128 27026805
    [Google Scholar]
  17. van de Hei S.J. Stoker N. Flokstra-de Blok B.M.J. Anticipated barriers and facilitators for implementing smart inhalers in asthma medication adherence management. NPJ Prim. Care Respir. Med. 2023 33 1 22 10.1038/s41533‑023‑00343‑w 37208358
    [Google Scholar]
  18. Mysovskikh I. Legg M. Demidenko S. Flowrate sensing and measurement in portable smart inhalers. Sensors 2024 24 21 6848 10.3390/s24216848 39517745
    [Google Scholar]
  19. Ari A. Fink J.B. Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin. Drug Deliv. 2020 17 2 133 144 10.1080/17425247.2020.1712356 31959028
    [Google Scholar]
  20. Wasserman R.L. Sheth K. Lincourt W.R. Locantore N.W. Rosenzweig J.C. Crim C. Real-world assessment of a metered-dose inhaler with integrated dose counter. Allergy Asthma Proc. 2006 27 6 486 492 10.2500/aap.2006.27.2921 17176783
    [Google Scholar]
  21. Drummond D. Roukema J. Pijnenburg M. Home monitoring in asthma: Towards digital twins. Curr. Opin. Pulm. Med. 2023 29 4 270 276 10.1097/MCP.0000000000000963 37102597
    [Google Scholar]
  22. Rogliani P. Ritondo B.L. Ora J. Cazzola M. Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: A network meta-analysis. Eur. Respir. J. 2020 56 3 2000625 10.1183/13993003.00625‑2020 32430423
    [Google Scholar]
  23. Nurgalieva L O’Callaghan D Doherty G Security and privacy of mhealth applications: A scoping review. IEEE Access 2020 8 104247 68 10.1109/ACCESS.2020.2999934
    [Google Scholar]
  24. Son J. Brennan P.F. Zhou S. A data analytics framework for smart asthma management based on remote health information systems with bluetooth-enabled personal inhalers. Manage. Inf. Syst. Q. 2020 44 1 285 304 10.25300/MISQ/2020/15092
    [Google Scholar]
  25. Himes B.E. Leszinsky L. Walsh R. Hepner H. Wu A.C. Mobile health and inhaler-based monitoring devices for asthma management. J. Allergy Clin. Immunol. Pract. 2019 7 8 2535 2543 10.1016/j.jaip.2019.08.034 31706485
    [Google Scholar]
  26. Sadafi H. De Backer W. Krestin G. De Backer J. Rapid deposition analysis of inhaled aerosols in human airways. Sci. Rep. 2024 14 1 24965 10.1038/s41598‑024‑75578‑9 39443597
    [Google Scholar]
  27. Cazzola M. Cavalli F. Usmani O.S. Rogliani P. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin. Drug Deliv. 2020 17 5 635 646 10.1080/17425247.2020.1739021 32130023
    [Google Scholar]
  28. Aundhia C. Parmar G. Talele C. Shah N. Talele D. Impact of artificial intelligence on drug development and delivery. Curr. Top. Med. Chem. 2025 25 10 1165 1184 10.2174/0115680266324522240725053634 39136506
    [Google Scholar]
  29. Budiarto A. Tsang K.C.H. Wilson A.M. Sheikh A. Shah S.A. Machine learning-based asthma attack prediction models from routinely collected electronic health records: Systematic scoping review. JMIR AI 2023 2 1 46717 10.2196/46717 38875586
    [Google Scholar]
  30. Chamaon D. Sportel E. Elferink E. van der Palen J. Validation of an AI-powered smart dry powder inhaler (RS01X) for asthma and copd in a clinical setting. Int. J. Chron. Obstruct. Pulmon. Dis. 2025 20 811 819 10.2147/COPD.S490684 40161395
    [Google Scholar]
  31. Levy M.L. Kocks J.W.H. Bosnic-Anticevich S. Uncovering patterns of inhaler technique and reliever use: The value of objective, personalized data from a digital inhaler. NPJ Prim. Care Respir. Med. 2024 34 1 23 10.1038/s41533‑024‑00382‑x 39164292
    [Google Scholar]
  32. Terenti M. Vatavu R.D. Wear + Touch: An exploration of wearables for vibrotactile feedback during touchscreen input. Int. J. Hum. Comput. Interact. 2025 41 10 5973 5991 10.1080/10447318.2024.2372145
    [Google Scholar]
  33. Kaaresoja T. Brewster S. Lantz V. Towards the temporally perfect virtual button: Touch-feedback simultaneity and perceived quality in mobile touchscreen press interactions. ACM Trans. Appl. Percept. 2014 11 2 1 25 10.1145/2611387
    [Google Scholar]
  34. Alkobaisi S. Safdar M.F. Pałka P.N.A. Artificial intelligence algorithms in asthma management: A review of data engineering, predictive models, and future implications. Appl. Sci. 2025 15 7 3609 10.3390/app15073609
    [Google Scholar]
  35. Margam R. Smart inhalers: Harnessing IoT for precise asthma management. Int. Educ. Res. J. 2024 10 1 10
    [Google Scholar]
  36. Krishnapriya V.S. Smart Inhaler: An application of IoMT. TechRxiv 2025 10.36227/techrxiv.175339509.94432308/v1
    [Google Scholar]
  37. Karthika M. Sreedharan J.K. Shevade M. Mathew C.S. Ray S. Artificial intelligence in respiratory care. Front Digital Health 2024 6 1502434 10.3389/fdgth.2024.1502434 39764208
    [Google Scholar]
  38. Babajide A Wakili A Barnett M Potter L Palmer X-L Jung W Safeguarding smart inhaler devices and patient privacy in respiratory health monitoring. arXiv250403730 2025 10.48550/arXiv.2504.03730
    [Google Scholar]
  39. Pleasants R.A. Chan A.H.Y. Mosnaim G. Integrating digital inhalers into clinical care of patients with asthma and chronic obstructive pulmonary disease. Respir. Med. 2022 205 107038 10.1016/j.rmed.2022.107038 36446239
    [Google Scholar]
  40. Lupin launches “Adhero,” first-of-its-kind connected smart device in India to support treatment of respiratory disease. 2019 Available from: https://www.lupin.com/lupin-launches-adhero-first-of-its-kind-connected-smart-device-in-india-to-support-treatment-of-respiratory-disease/
  41. Propeller health monitoring. US Patent 20180079522A1 2018
    [Google Scholar]
  42. Asthma A.I. 2018 Available from: https://findair.eu/asthmaai/
  43. Melvin E. Cushing A. Tam A. Kitada R. Manice M. Assessing the use of BreatheSmart® mobile technology in adult patients with asthma: A remote observational study. BMJ Open Respir. Res. 2017 4 1 000204 10.1136/bmjresp‑2017‑000204 29071077
    [Google Scholar]
  44. Hatamian M. Edalat P. Smart inhaler device with automated dose delivery, measurement, and management. US Patent 11090449B2 2021
    [Google Scholar]
  45. Zabczyk C. Blakey J.D. The effect of connected “smart” inhalers on medication adherence. Front Med Technol 2021 3 657321 10.3389/fmedt.2021.657321 35047916
    [Google Scholar]
  46. Sportel E.T. Oude Wolcherink M.J. van der Palen J. Does immediate smart feedback on therapy adherence and inhalation technique improve asthma control in children with uncontrolled asthma? A study protocol of the IMAGINE I study. Trials 2020 21 1 801 10.1186/s13063‑020‑04694‑4 32943094
    [Google Scholar]
  47. Chan A. De Simoni A. Wileman V. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Libr. 2022 2022 6 CD013030 10.1002/14651858.CD013030.pub2 35691614
    [Google Scholar]
  48. van de Hei S.J. van den Berg L.N. Poot C.C. Long-term effectiveness of a digital inhaler on medication adherence and clinical outcomes in adult asthma patients in primary care: The cluster randomized controlled ACCEPTANCE trial. J. Allergy Clin. Immunol. Pract. 2025 13 7 1693 1704 10.1016/j.jaip.2025.03.013 40118212
    [Google Scholar]
  49. Aung H. Tan R. Flynn C. Digital remote maintenance inhaler adherence interventions in COPD: A systematic review and meta-analysis. Eur. Respir. Rev. 2024 33 174 240136 10.1183/16000617.0136‑2024 39631930
    [Google Scholar]
  50. Kokori E. Olatunji G. Mustapha M.J. The potential of smart inhaler for asthma management in Sub-Saharan Africa. Ann. Med. Surg. 2024 86 5 2408 2410 10.1097/MS9.0000000000002009 38694290
    [Google Scholar]
  51. van de Hei S.J. Poot C.C. van den Berg L.N. Effectiveness, usability and acceptability of a smart inhaler programme in patients with asthma: Protocol of the multicentre, pragmatic, open-label, cluster randomised controlled ACCEPTANCE trial. BMJ Open Respir. Res. 2022 9 1 001400 10.1136/bmjresp‑2022‑001400 36522130
    [Google Scholar]
  52. Duan J Chen X Fan D Experience of using electronic inhaler monitoring devices for patients with chronic obstructive pulmonary disease or asthma: Systematic review of qualitative studies. JMIR Mhealth Uhealth 2025 13 v13i1e57645 10.2196/57645 40378281
    [Google Scholar]
  53. Shandhi M.M.H. Singh K. Janson N. Assessment of ownership of smart devices and the acceptability of digital health data sharing. NPJ Digit. Med. 2024 7 1 44 10.1038/s41746‑024‑01030‑x 38388660
    [Google Scholar]
  54. Zhuang Y. Sheets L.R. Chen Y.W. Shae Z.Y. Tsai J.J.P. Shyu C.R. A patient-centric health information exchange framework using blockchain technology. IEEE J. Biomed. Health Inform. 2020 24 8 2169 2176 10.1109/JBHI.2020.2993072 32396110
    [Google Scholar]
  55. Evidence reviews for smart inhalers. 2024 Available from: http://www.ncbi.nlm.nih.gov/books/NBK611998/
  56. van de Hei S.J. Kim C.H. Honkoop P.J. Long-term cost-effectiveness of digital inhaler adherence technologies in difficult-to-treat asthma. J. Allergy Clin. Immunol. Pract. 2023 11 10 3064 3073.e15 10.1016/j.jaip.2023.06.051 37406806
    [Google Scholar]
  57. Howard S. Lang A. Sharples S. Shaw D. What are the pros and cons of electronically monitoring inhaler use in asthma? A multistakeholder perspective. BMJ Open Respir. Res. 2016 3 1 000159 10.1136/bmjresp‑2016‑000159 27933181
    [Google Scholar]
  58. Feng X. Shi Y. Zhang Y. Lei F. Ren R. Tang X. Opportunities and challenges for inhalable nanomedicine formulations in respiratory diseases: A review. Int. J. Nanomedicine 2024 19 1509 1538 10.2147/IJN.S446919 38384321
    [Google Scholar]
  59. Cojocaru E. Petriș O.R. Cojocaru C. Nanoparticle-based drug delivery systems in inhaled therapy: Improving respiratory medicine. Pharmaceuticals 2024 17 8 1059 10.3390/ph17081059 39204164
    [Google Scholar]
  60. Chen X. Tang Z. Novel application of nanomedicine for the treatment of acute lung injury: A literature review. Ther. Adv. Respir. Dis. 2024 18 17534666241244974 10.1177/17534666241244974 38616385
    [Google Scholar]
  61. Doroudian M. O’ Neill A. Loughlin M.R. Prina-Mello A. Volkov Y. Donnelly S.C. Nanotechnology in pulmonary medicine. Curr. Opin. Pharmacol. 2021 56 85 92 10.1016/j.coph.2020.11.002 33341460
    [Google Scholar]
  62. Fernández-García R. Fraguas-Sánchez A.I. Nanomedicines for pulmonary drug delivery: Overcoming barriers in the treatment of respiratory infections and lung cancer. Pharmaceutics 2024 16 12 1584 10.3390/pharmaceutics16121584 39771562
    [Google Scholar]
  63. Chen M. Shou Z. Jin X. Chen Y. Emerging strategies in nanotechnology to treat respiratory tract infections: Realizing current trends for future clinical perspectives. Drug Deliv. 2022 29 1 2442 2458 10.1080/10717544.2022.2089294 35892224
    [Google Scholar]
  64. Shaik N y P. Nanocarriers and their types for targeted drug delivery. Int. J. Pharm. Sci. Rev. Res. 2022 77 1 21 28 10.47583/ijpsrr.2022.v77i01.004
    [Google Scholar]
  65. Menon J.U. Ravikumar P. Pise A. Gyawali D. Hsia C.C.W. Nguyen K.T. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomater. 2014 10 6 2643 2652 10.1016/j.actbio.2014.01.033 24512977
    [Google Scholar]
  66. Al-Nemrawi N.K. Darweesh R.S. Al-shriem L.A. Polymeric nanoparticles for inhaled vaccines. Polymers 2022 14 20 4450 10.3390/polym14204450 36298030
    [Google Scholar]
  67. Elhissi A. Liposomes for pulmonary drug delivery: The role of formulation and inhalation device design. Curr. Pharm. Des. 2017 23 3 362 372 10.2174/1381612823666161116114732 27848886
    [Google Scholar]
  68. Leong E.W.X. Ge R. Lipid nanoparticles as delivery vehicles for inhaled therapeutics. Biomedicines 2022 10 9 2179 10.3390/biomedicines10092179 36140280
    [Google Scholar]
  69. Shek P.N. Suntres Z.E. Brooks J.I. Liposomes in pulmonary applications: Physicochemical considerations, pulmonary distribution and antioxidant delivery. J. Drug Target. 1994 2 5 431 442 10.3109/10611869408996819 7704488
    [Google Scholar]
  70. Mišík O. Kejíková J. Cejpek O. Nebulization and in vitro upper airway deposition of liposomal carrier systems. Mol. Pharm. 2024 21 4 1848 1860 10.1021/acs.molpharmaceut.3c01146 38466817
    [Google Scholar]
  71. Alwani S. Wasan E.K. Badea I. Solid lipid nanoparticles for pulmonary delivery of biopharmaceuticals: A review of opportunities, challenges, and delivery applications. Mol. Pharm. 2024 21 7 3084 3102 10.1021/acs.molpharmaceut.4c00128 38828798
    [Google Scholar]
  72. Gaspar D.P. Gaspar M.M. Eleutério C.V. Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery. Mol. Pharm. 2017 14 9 2977 2990 10.1021/acs.molpharmaceut.7b00169 28809501
    [Google Scholar]
  73. Dubey S.K. Salunkhe S. Agrawal M. Understanding the pharmaceutical aspects of dendrimers for the delivery of anticancer drugs. Curr. Drug Targets 2020 21 6 528 540 10.2174/1389450120666191031092259 31670619
    [Google Scholar]
  74. Bai S. Ahsan F. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm. Res. 2009 26 3 539 548 10.1007/s11095‑008‑9769‑y 19034631
    [Google Scholar]
  75. Costa M.P. Abdu J.O.C. de Moura M.F.C.S. Exploring the potential of plga nanoparticles for enhancing pulmonary drug delivery. Mol. Pharm. 2025 22 7 3542 3562 10.1021/acs.molpharmaceut.5c00118 40479726
    [Google Scholar]
  76. Alghareeb S. Asare-Addo K. Conway B.R. Adebisi A.O. PLGA nanoparticles for nasal drug delivery. J. Drug Deliv. Sci. Technol. 2024 95 105564 10.1016/j.jddst.2024.105564
    [Google Scholar]
  77. Costabile G. Conte G. Brusco S. State-of-the-art review on inhalable lipid and polymer nanocarriers: Design and development perspectives. Pharmaceutics 2024 16 3 347 10.3390/pharmaceutics16030347 38543241
    [Google Scholar]
  78. ARIKAYCE 2018 Available from: https://www.arikayce.com
  79. Weber S. Zimmer A. Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art. Eur. J. Pharm. Biopharm. 2014 86 1 7 22 10.1016/j.ejpb.2013.08.013 24007657
    [Google Scholar]
  80. Patel D.K. Patel K. Thakkar H.P. Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies. J. Appl. Pharm. Sci. 2020 10 6 126 141 10.7324/JAPS.2020.10617
    [Google Scholar]
  81. Araújo R.V. Santos S.S. Igne Ferreira E. Giarolla J. New advances in general biomedical applications of PAMAM dendrimers. Molecules 2018 23 11 2849 10.3390/molecules23112849 30400134
    [Google Scholar]
  82. Nasr M. Najlah M. D’Emanuele A. Elhissi A. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int. J. Pharm. 2014 461 1-2 242 250 10.1016/j.ijpharm.2013.11.023 24275446
    [Google Scholar]
  83. Gad S. Yousry A. Hassan T. Aidy. Nanocarriers as pulmonary drug delivery systems. Rec Pharma Biomed Sci 2022 6 3 113 119 10.21608/rpbs.2022.143936.1150
    [Google Scholar]
  84. Song X. Zhang Y. Tang Z. Du L. Advantages of nanocarriers for basic research in the field of traumatic brain injury. Neural Regen. Res. 2024 19 2 237 245 10.4103/1673‑5374.379041 37488872
    [Google Scholar]
  85. Mansour H. Haemosu, Wu X. Nanomedicine in pulmonary delivery. Int. J. Nanomedicine 2009 4 299 319 10.2147/IJN.S4937 20054434
    [Google Scholar]
  86. Wang Y. Huang R. Feng S. Mo R. Advances in nanocarriers for targeted drug delivery and controlled drug release. Chin. J. Nat. Med. 2025 23 5 513 528 10.1016/S1875‑5364(25)60861‑2 40383609
    [Google Scholar]
  87. Lee J.H. Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem. Eng. Sci. 2015 125 75 84 10.1016/j.ces.2014.08.046 25684779
    [Google Scholar]
  88. Pal R. Pandey P. Chawra H.S. Khan Z. Nano drug delivery carriers (nanocarriers): A promising targeted strategy in tuberculosis and pain treatment. Pharm. Nanotechnol. 2025 13 10 10.2174/0122117385367493250224103839 40059418
    [Google Scholar]
  89. Shi P. Cheng Z. Zhao K. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. J. Nanobiotechnology 2023 21 1 103 10.1186/s12951‑023‑01826‑1 36944946
    [Google Scholar]
  90. Mansour H.M. Muralidharan P. Hayes D. Inhaled nanoparticulate systems: Composition, manufacture and aerosol delivery. J. Aerosol Med. Pulm. Drug Deliv. 2024 37 4 202 218 10.1089/jamp.2024.29117.mk 39172256
    [Google Scholar]
  91. Abaidullah N. Muhammad K. Waheed Y. Delving into nanoparticle systems for enhanced drug delivery technologies. AAPS PharmSciTech 2025 26 3 74 10.1208/s12249‑025‑03063‑1 40038143
    [Google Scholar]
  92. Stavis S.M. Fagan J.A. Stopa M. Liddle J.A. Nanoparticle manufacturing - heterogeneity through processes to products. ACS Appl. Nano Mater. 2018 1 9 4358 4385 10.1021/acsanm.8b01239
    [Google Scholar]
  93. Bierkandt F.S. Leibrock L. Wagener S. Laux P. Luch A. The impact of nanomaterial characteristics on inhalation toxicity. Toxicol. Res. 2018 7 3 321 346 10.1039/c7tx00242d 30090585
    [Google Scholar]
  94. Rodríguez-Gómez F.D. Monferrer D. Penon O. Rivera-Gil P. Regulatory pathways and guidelines for nanotechnology-enabled health products: A comparative review of EU and US frameworks. Front. Med. 2025 12 1544393 10.3389/fmed.2025.1544393 40109724
    [Google Scholar]
  95. Mangla B. Kumar P. Javed S. Pathan T. Ahsan W. Aggarwal G. Regulating nanomedicines: Challenges, opportunities, and the path forward. Nanomedicine (Lond.) 2025 20 15 1911 1927 10.1080/17435889.2025.2533107 40657903
    [Google Scholar]
  96. Kotta S. Aldawsari H.M. Badr-Eldin S.M. Aerosol delivery of surfactant liposomes for management of pulmonary fibrosis: An approach supporting pulmonary mechanics. Pharmaceutics 2021 13 11 1851 10.3390/pharmaceutics13111851 34834265
    [Google Scholar]
  97. Rudokas M. Najlah M. Alhnan M.A. Elhissi A. Liposome delivery systems for inhalation: A critical review highlighting formulation issues and anticancer applications. Med. Princ. Pract. 2016 25 Suppl. 2 60 72 10.1159/000445116 26938856
    [Google Scholar]
  98. Xu Y. Parra-Ortiz E. Wan F. Insights into the mechanisms of interaction between inhalable lipid-polymer hybrid nanoparticles and pulmonary surfactant. J. Colloid Interface Sci. 2023 633 511 525 10.1016/j.jcis.2022.11.059 36463820
    [Google Scholar]
  99. Harishchandra R.K. Saleem M. Galla H.J. Nanoparticle interaction with model lung surfactant monolayers. J. R. Soc. Interface 2010 7 Suppl. 1 S15 S26 10.1098/rsif.2009.0329.focus 19846443
    [Google Scholar]
  100. Bai X. Xu M. Liu S. Hu G. Computational investigations of the interaction between the cell membrane and nanoparticles coated with a pulmonary surfactant. ACS Appl. Mater. Interfaces 2018 10 24 20368 20376 10.1021/acsami.8b06764 29808987
    [Google Scholar]
  101. Azarnezhad A. Samadian H. Jaymand M. Sobhani M. Ahmadi A. Toxicological profile of lipid-based nanostructures: Are they considered as completely safe nanocarriers? Crit. Rev. Toxicol. 2020 50 2 148 176 10.1080/10408444.2020.1719974 32053030
    [Google Scholar]
  102. Mousseau F. Berret J.F. The role of surface charge in the interaction of nanoparticles with model pulmonary surfactants. Soft Matter 2018 14 28 5764 5774 10.1039/C8SM00925B 29989135
    [Google Scholar]
  103. Valavanidis A. Vlachogianni T. Fiotakis K. Loridas S. Perdicaris S. Potential toxicity and safety evaluation of nanomaterials for the respiratory system and lung cancer. Lung Cancer 2013 4 71 82 10.2147/LCTT.S23216 28210136
    [Google Scholar]
  104. Lee Y. Jeong M. Park J. Jung H. Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 2023 55 10 2085 2096 10.1038/s12276‑023‑01086‑x 37779140
    [Google Scholar]
  105. Gyanani V. Goswami R. Key design features of lipid nanoparticles and electrostatic charge-based lipid nanoparticle targeting. Pharmaceutics 2023 15 4 1184 10.3390/pharmaceutics15041184 37111668
    [Google Scholar]
  106. Jung W. Yoon C. Jeon S. Biodistribution and toxicity following a single or repeated pharyngeal aspiration of titanium dioxide nanoparticles: Determination of maximum allowable dose level. Toxicol. Appl. Pharmacol. 2025 503 117477 10.1016/j.taap.2025.117477 40681002
    [Google Scholar]
  107. Qiao H. Liu W. Gu H. Wang D. Wang Y. The transport and deposition of nanoparticles in respiratory system by inhalation. J. Nanomater. 2015 2015 1 394507 10.1155/2015/394507
    [Google Scholar]
  108. Boppana S.H. Kutikuppala L.V.S. Sharma S. Current approaches in smart nano-inspired drug delivery: A narrative review. Health Sci. Rep. 2024 7 4 2065 10.1002/hsr2.2065 38660006
    [Google Scholar]
  109. Mahmoud D.E. Hosseini S.H. Rathore H.A. Alkilany A.M. Heise A. Elhissi A. Inhalable nanotechnology-based drug delivery systems for the treatment of inflammatory lung diseases. Pharmaceutics 2025 17 7 893 10.3390/pharmaceutics17070893 40733101
    [Google Scholar]
  110. Al-Anazi S. Al-Omari A. Alanazi S. Artificial intelligence in respiratory care: Current scenario and future perspective. Ann. Thorac. Med. 2024 19 2 117 130 10.4103/atm.atm_192_23 38766378
    [Google Scholar]
  111. Tan L. Nguyen N. Lopez E. Artificial intelligence in the management of asthma: A review of a new frontier in patient care. J. Asthma Allergy 2025 18 1179 1191 10.2147/JAA.S535264 40851769
    [Google Scholar]
  112. Biddiscombe M.F. Usmani O.S. Is there room for further innovation in inhaled therapy for airways disease? Breathe 2018 14 3 216 224 10.1183/20734735.020318 30186519
    [Google Scholar]
  113. Alhazmi A.K. Alanazi M.A. Alshehry A.H. Intelligent millimeter-wave system for human activity monitoring for telemedicine. Sensors 2024 24 1 268 10.3390/s24010268 38203130
    [Google Scholar]
  114. Feinstein M. Katz D. Demaria S. Hofer I.S. Remote monitoring and artificial intelligence: Outlook for 2050. Anesth. Analg. 2024 138 2 350 357 10.1213/ANE.0000000000006712 38215713
    [Google Scholar]
  115. Kumar R. Mehta P. Shankar K.R. Nanotechnology-assisted metered-dose inhalers (MDIs) for high-performance pulmonary drug delivery applications. Pharm. Res. 2022 39 11 2831 2855 10.1007/s11095‑022‑03286‑y 35552983
    [Google Scholar]
  116. Duvall M.N. FDA regulation of nanotechnology. 2012 Available from: https://www.bdlaw.com/content/uploads/2018/06/fda-regulation-of-nanotechnology.pdf
    [Google Scholar]
  117. Drug products, including biological products, that contain nanomaterials - guidance for industry. 2022 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry
  118. Aung H.W.W. Murphy A. Greening N.J. The evolving landscape of digital inhaler platforms and adherence support in chronic airways disease. Chron. Respir. Dis. 2025 22 14799731251366969 10.1177/14799731251366969 40779701
    [Google Scholar]
  119. Pharmaceutical quality of inhalation and nasal products - Scientific guideline. 2025 Available from: https://www.ema.europa.eu/en/pharmaceutical-quality-inhalation-nasal-products-scientific-guideline
  120. Requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD) - Scientific guideline. 2025 Available from: https://www.ema.europa.eu/en/requirements-demonstrating-therapeutic-equivalence-between-orally-inhaled-products-oip-asthma-chronic-obstructive-pulmonary-disease-copd-scientific-guideline
  121. Au C.Y. Koh K.J.X. Lim H.F. Bhagat A.A.S. Metered-dose inhaler spacer with integrated spirometer for home-based asthma monitoring and drug uptake. Bioengineering 2024 11 6 552 10.3390/bioengineering11060552 38927788
    [Google Scholar]
  122. Eappen P. Vajjhala N.R. Zikos D. Davidson K.P. Information Systems Engineering and Management. Cham Springer Nature Switzerland 2025 63
    [Google Scholar]
  123. Tyler J. Choi S.W. Tewari M. Real-time, personalized medicine through wearable sensors and dynamic predictive modeling: A new paradigm for clinical medicine. Curr. Opin. Syst. Biol. 2020 20 17 25 10.1016/j.coisb.2020.07.001 32984661
    [Google Scholar]
  124. Zheng Z. Zhu R. Peng I. Xu Z. Jiang Y. Wearable and implantable biosensors: Mechanisms and applications in closed-loop therapeutic systems. J. Mater. Chem. B Mater. Biol. Med. 2024 12 35 8577 8604 10.1039/D4TB00782D 39138981
    [Google Scholar]
  125. Cicha I. Priefer R. Severino P. Souto E.B. Jain S. Biosensor-integrated drug delivery systems as new materials for biomedical applications. Biomolecules 2022 12 9 1198 10.3390/biom12091198 36139035
    [Google Scholar]
  126. Jadhav M.R. Wankhede P.R. Srivastava S. Bhargaw H.N. Singh S. Breath-based biosensors and system development for noninvasive detection of diabetes: A review. Diabetes Metab. Syndr. 2024 18 1 102931 10.1016/j.dsx.2023.102931 38171153
    [Google Scholar]
  127. Honkoop P. Usmani O. Bonini M. The current and future role of technology in respiratory care. Pulm. Ther. 2022 8 2 167 179 10.1007/s41030‑022‑00191‑y 35471689
    [Google Scholar]
  128. Mosnaim G.S. Greiwe J. Jariwala S.P. Pleasants R. Merchant R. Digital inhalers and remote patient monitoring for asthma. J. Allergy Clin. Immunol. Pract. 2022 10 10 2525 2533 10.1016/j.jaip.2022.06.026 35779779
    [Google Scholar]
  129. Chandrakar M. Telehealth and digital tools enhancing healthcare access in rural systems. Discover Public Health 2024 21 1 144 10.1186/s12982‑024‑00271‑1
    [Google Scholar]
  130. Shokouhmand S. Bhatt S. Faezipour M. Artificial intelligence in respiratory health: A review of ai-driven analysis of oral and nasal breathing sounds for pulmonary assessment. Electronics 2025 14 10 1994 10.3390/electronics14101994
    [Google Scholar]
/content/journals/crmr/10.2174/011573398X448056251210224544
Loading
Smart Inhalers and Nanotechnology-driven Inhalation Drug Delivery System: A Review
Bentham Science Publishers ; https://doi.org/10.2174/011573398X448056251210224544
/content/journals/crmr/10.2174/011573398X448056251210224544
/content/journals/crmr/10.2174/011573398X448056251210224544
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: digital health ; nanotechnology ; medication adherence ; nanoparticles ; inhalation drug delivery ; Smart inhalers

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test